Publications by authors named "Harald Gschaidmeier"

Claim this Profile
E
Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.
Klemens Budde, Thomas Becker, Wolfgang Arns, Claudia Sommerer, Petra Reinke, Harald Gschaidmeier

Lancet· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Everolimus in patients with autosomal dominant polycystic kidney disease.
Gerd Walz, Klemens Budde, Marwan Mannaa, Jens Nürnberger, Christoph Wanner, Harald Gschaidmeier

N Engl J Med· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The neuronal 5-HT3 receptor network after 20 years of research--evolving concepts in management of pain and inflammation.
Lothar Faerber, Sabine Drechsler, Stephan Ladenburger, Harald Gschaidmeier, Wolfgang Fischer

Eur J Pharmacol· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
Barbara Wassmann, Heike Pfeifer, Nicola Goekbuget, Dietrich W Beelen, Joachim Beck, Harald Gschaidmeier

Blood· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative bioavailability of the microemulsion formulation of cyclosporine (Neoral) with a generic dispersion formulation (Cicloral) in young healthy male volunteers.
Frieder Kees, Michael Bucher, Frank Schweda, Harald Gschaidmeier, Juergen Burhenne

Ther Drug Monit· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progression.
Jie Chen, Christoph Röcken, Barbara Nitsche, Christian Hosius, Harald Gschaidmeier

Cancer Lett· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study.
Georg Hess, Donald Bunjes, Wolfgang Siegert, Rainer Schwerdtfeger, Georg Ledderose, Harald Gschaidmeier

J Clin Oncol· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
Barbara Wassmann, Heike Pfeifer, Michael Stadler, Martin Bornhaüser, Gesine Bug, Harald Gschaidmeier

Blood· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML).
Thomas Kindler, Frank Breitenbuecher, Stefan Kasper, Eli Estey, Francis Giles, Harald Gschaidmeier

Blood· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia.
Thomas Kindler, Frank Breitenbuecher, Andreas Marx, Joachim Beck, Georg Hess, Harald Gschaidmeier

Blood· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib.
Barbara Wassmann, Heike Pfeifer, Urban J Scheuring, Anja Binckebanck, Nicola Gökbuget, Harald Gschaidmeier

Blood· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate.
Heike Pfeifer, Barbara Wassmann, Wolf-Karsten Hofmann, Martina Komor, Urban Scheuring, Harald Gschaidmeier

Clin Cancer Res· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current results on the use of imatinib mesylate in patients with relapsed Philadelphia chromosome positive leukemia after allogeneic or syngeneic hematopoietic stem cell transplantation.
Andrew J Ullmann, Georg Hess, Karin Kolbe, A Friedrich-Freksa, Ralf G Meyer, Harald Gschaidmeier

Keio J Med· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imatinib in Philadelphia chromosome-positive chronic phase CML patients: molecular and cytogenetic response rates and prediction of clinical outcome.
Philipp Le Coutre, Karl-Anton Kreuzer, Il-Kang Na, Michaela Schwarz, Joachim Lupberger, Harald Gschaidmeier

Am J Hematol· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia.
Wolf-Karsten Hofmann, Martina Komor, Barbara Wassmann, Letetia C Jones, Harald Gschaidmeier

Blood· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Normalization of previously shortened telomere length under treatment with imatinib argues against a preexisting telomere length deficit in normal hematopoietic stem cells from patients with chronic myeloid leukemia.
Tim H Brummendorf, Inci Ersoz, Ulrike Hartmann, Stefan Balabanov, Holger Wolke, Harald Gschaidmeier

Ann N Y Acad Sci· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML.
Thomas Kindler, Frank Breitenbuecher, Andreas Marx, Georg Hess, Harald Gschaidmeier

Blood· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571).
Urban J Scheuring, Heike Pfeifer, Barbara Wassmann, Patrick Bruck, Johannes Atta, Harald Gschaidmeier

Blood· January 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia.
Andreas Burchert, Stefan Wölfl, Manuel Schmidt, Cornelia Brendel, Barbara Denecke, Harald Gschaidmeier

Blood· January 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Telomere length in peripheral blood granulocytes reflects response to treatment with imatinib in patients with chronic myeloid leukemia.
Tim H Brümmendorf, Inci Ersöz, Ulrike Hartmann, Kerol Bartolovic, Stefan Balabanov, Harald Gschaidmeier

Blood· January 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo.
Stephan Fellner, Björn Bauer, David S Miller, Martina Schaffrik, Martina Fankhänel, Harald Gschaidmeier

J Clin Invest· November 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation.
Wolf-K Hofmann, Letetia C Jones, Nathan A Lemp, Sven de Vos, Harald Gschaidmeier

Blood· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study.
Wolf K Hofmann, Sven de Vos, David Elashoff, Harald Gschaidmeier, Dieter Hoelzer

Lancet· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis